StreetInsider.com News Articles

Form 4 Dianthus Therapeutics, For: Jul 09 Filed by: Savitz Ryan

Mon, 13 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260713/26763103.html

Form 4 Dianthus Therapeutics, For: Jul 09 Filed by: Savitz Ryan

Mon, 13 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260713/26763103.html

Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan

Thu, 09 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260709/26753526.html

Form 144 Dianthus Therapeutics, Filed by: Savitz Ryan

Thu, 09 Jul 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260709/26753526.html

Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)

Thu, 02 Jul 2026 16:01:00 -0400

NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 58,000 shares of the Company's

Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)

Thu, 02 Jul 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 58,000 shares of the Company's

Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)

Thu, 02 Jul 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 58,000 shares of the Company's

Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)

Thu, 02 Jul 2026 16:01:00 -0400

The inducement grants consist of non-qualified stock options to purchase an aggregate of 58,000 shares of the Company's

Dianthus starts Phase 3 trial of claseprubart in myasthenia gravis

Mon, 29 Jun 2026 07:01:54 -0400

Dianthus Therapeutics (Nasdaq: DNTH) announced the initiation of the EMERGE Phase 3 trial evaluating claseprubart in generalized Myasthenia Gravis (gMG), with top-line results expected in the second half of 2028.

The global, randomized, multicenter, placebo-controlled trial will enroll approximately 195 participants who are acetylcholine receptor antibody positive (AChR+). Following a loading dose, claseprubart 300mg/2mL will be administered via subcutaneous injection every two weeks or every four weeks. The primary endpoint is the change from baseline in the Myasthenia Gravis Activities of Daily Living Scale compared to placebo.

Secondary efficacy endpoints include the Quantitative Myasthenia Gravis scale, Minimal Symptom Expression, Myasthenia Gravis Composite

Dianthus starts Phase 3 trial of claseprubart in myasthenia gravis

Mon, 29 Jun 2026 07:01:54 -0400

Secondary efficacy endpoints include the Quantitative Myasthenia Gravis scale, Minimal Symptom Expression, Myasthenia Gravis Composite

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

Mon, 29 Jun 2026 07:00:00 -0400

EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H’28

Advancing a neuromuscular franchise with claseprubart, a highly potent investigational classical pathway inhibitor, across generalized Myasthenia Gravis (gMG), Multifocal Motor Neuropathy (MMN) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with best-in-disease, pipeline-in-a-product potential

NEW YORK and WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

Mon, 29 Jun 2026 07:00:00 -0400

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

Mon, 29 Jun 2026 07:00:00 -0400

Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis

Mon, 29 Jun 2026 07:00:00 -0400

Form 4 Dianthus Therapeutics, For: Jun 17 Filed by: Veness Adam M

Thu, 18 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260618/26666559.html

Form 4 Dianthus Therapeutics, For: Jun 17 Filed by: Veness Adam M

Thu, 18 Jun 2026 16:30:00 -0400

si-local-file:///var/storage/secattach/20260618/26666559.html

Form 144 Dianthus Therapeutics, Filed by: Veness Adam M

Wed, 17 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260617/26660466.html

Form 144 Dianthus Therapeutics, Filed by: Veness Adam M

Wed, 17 Jun 2026 16:33:00 -0400

si-local-file:///var/storage/secattach/20260617/26660466.html

Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'

Fri, 12 Jun 2026 14:53:19 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

The analyst comments "DNTH reported additional data from Part A of their Phase 3 CAPTIVATE study evaluating claseprubart in CIDP showing a 75% responder rate in the first n=40 patients (up to 13 weeks), which is notably higher than the overall rate in the riliprubart (SNY) Phase 2 at Week 24 (~55%). Mean INCAT score change in responders was -1.6 at last evaluable visit (Week 13 or earlier), and substantial improvements were seen broadly across grip strength, MRC-SS, and I-RODS (notably patient-reported)

Raymond James on Dianthus Therapeutics (DNTH) Amid 8% Gain: 'Incrementally More Bullish On The CIDP Program (again)'

Fri, 12 Jun 2026 14:53:19 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $125.00 price target on Dianthus Therapeutics (NASDAQ: DNTH).

Form 8-K Dianthus Therapeutics, For: Jun 12

Fri, 12 Jun 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260612/26638162.html

Form 8-K Dianthus Therapeutics, For: Jun 12

Fri, 12 Jun 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260612/26638162.html

Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'

Wed, 10 Jun 2026 16:10:32 -0400

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $200.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)

The analyst comments "Sanofi (SNY)'s decision to stop the Phase 3 MOBILIZE study of riliprubart in SOC-refractory CIDP at the pre-specified interim has driven fair investor scrutiny to DNTH's CAPTIVATE program, but on balance we see today's news as constructive for claseprubart. Mgmt views it as a net positive, and we agree, for four reasons: (1) potency — claseprubart is ~7× more potent than riliprubart at IC90, but Sanofi was only dosing ~4× higher, implying riliprubart likely failed to achieve the target coverage required

Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'

Wed, 10 Jun 2026 16:10:32 -0400

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $200.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)

Dianthus Therapeutics (DNTH) PT Raised to $132 at Jefferies

Wed, 10 Jun 2026 15:52:12 -0400

Jefferies analyst Maury Raycroft raised the price target on Dianthus Therapeutics (NASDAQ: DNTH) to $132.00 (from $110.00) while maintaining a Buy rating.